PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 1 | 3 | 177-182
Article title

Podstawy diagnostyki i leczenia jaskry według czwartej edycji zaleceń Europejskiego Towarzystwa Jaskrowego

Content
Title variants
EN
Fundamentals of diagnosis and therapy of glaucoma according to the fourth edition of guidelines of the European Society of Ophthalmology
Languages of publication
PL
Abstracts
EN
The guidelines of the European Glaucoma Society (EGS) define standards for diagnosis and management of glaucoma. The following article summarises the main findings contained in the fourth edition of EGS 2014. A monotherapy is suggested as the first-line treatment, and in case of the absence of its effectiveness changing the drug to another one or adding a second preparation is recommended. For the efficacy and safety of treatment, the preferred drugs are complex ones, constituting a combination of two active substances in one formulation. The need for more frequent condition monitoring of a patient whose treatment is carried out with generic drugs is important. The treatment of glaucoma must also take into consideration modern laser and surgical methods.
PL
Wytyczne Europejskiego Towarzystwa Jaskrowego (EGS) określają standardy diagnostyki i postępowania w jaskrze. W poniższym artykule podsumowano najważniejsze ustalenia zawarte w czwartej edycji EGS z 2014 r. Jako leczenie pierwszego rzutu rekomendowana jest monoterapia, a gdy okaże się ona nieefektywna, zaleca się zmianę leku na inny lub dołączenie drugiego preparatu. Ze względu na skuteczność i bezpieczeństwo terapii preferowane są leki złożone, stanowiące połączenie dwóch składników czynnych w jednej formule. Zwraca się uwagę na konieczność częstszego monitorowania stanu pacjenta leczonego lekami odtwórczymi. W terapii jaskry należy też uwzględnić nowoczesne metody laserowe oraz chirurgiczne.
Keywords
Discipline
Publisher
Journal
Year
Volume
1
Issue
3
Pages
177-182
Physical description
References
  • 1. European Glaucoma Society. Terminology and guidelines for glaucoma. The fourth edition, Dogma, Savona, Italy 2014.
  • 2. The AGIS Investigators. The Advanced glaucoma intervention study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-440.
  • 3. Hodapp E, Parrish RK, Anderson DR. Clinical decisions in glaucoma. CV Mosby Company, St Louis 1993.
  • 4. Mills RP, Budenz DL, Lee PP, et al. Categorising the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol 2006; 141: 24-30.
  • 5. Katsimpris JM, Theoulakis PE, Papadopoulos GE, et al. Ocular pulse amplitude measurement using Pascal dynamic contour tonometer in glaucoma patients. Klin Monbl Augenheilkd 2014; 23: 363-7.
  • 6. Heijl A, Leske MC, Bengtsson B. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120(10): 1268-79.
  • 7. Van der Valk R, Webers CA, Schouten JS. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a metaanalysis of randomized clinical trials. Ophthalmology 2005; 112(7): 1177-85.
  • 8. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007; 24(12): 1007-1016.
  • 9. Denis P, Andrew R, Wells D. A comparison of morning and evening installation of a combination travoprost 0,004%/timolol 0,5% ophthalmic solution. Eur J Ophthalmol 2005; 3: 407-415.
  • 10. Aung T, Laganowska G, Hernandez-Paredes T, et al. Twice-daily brinzolamide /brimonidine fixed-combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 2014, Jul 23: 1-8 [Epub ahead of print].
  • 11. Erb C, Lanzl I, Seidova S-F, et al. Preservative-free tafluprost 0,0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther 2011; 28(7): 575-585.
  • 12. Gandolfi S, Predes T, Goldberg I, et al. Travoprost BAK-free Clinical Study Group: comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open angle glaucoma. Eur J Ophthalmol 2012; 22(1): 34-44.
  • 13. Katz G, Springs CL, Craven ER, et al. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK–preserved latanoprost or BAK-free travoprost. Clinical Ophthalmology 2010; 4: 1253-1261.
  • 14. Ho J-D., Hu C-C, Lin H-C. Antiglaucoma medications during pregnancy and the risk of low birth weight: a population-based study. Br J Ophthalmol 2009; 93: 1283-1286.
  • 15. [No authors listed] The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7 Results. Am J Ophthalmol 1995; 120(6): 718-31.
  • 16. Katz LJ, Steinmann WC, Kabir A. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma 2012; 21(7): 460-8.
  • 17. Denis P, Lafuma A, Berdeaux G. Medical outcomes of glaucoma therapy from a nationwide representative survey. Clin Drug Invest 2004; 24(6): 343-352.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-1c582cd9-166e-4d02-91a1-b145dcd7382e
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.